Gilead Sprints To A Profit-Taking Zone After Riding Covid Drug To Beat And Raise
Gilead stock sprinted to a profit-taking zone Thursday after Gilead Sciences rode its Covid treatment to another beat and raise. Continue reading View comments
- Supported exchanges /
- SA /
- GILD34.SA
Gilead Sciences Inc (GILD34 SA) stock market data APIs
R$270.7
0.97(0.4%)
as of November 13, 2024
Price chart is built with Anychart
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.
Gilead Sciences Inc Financial Data Overview
| 269.73 | |
| 270.7 | |
| - | |
| 270.7 | |
| 269.73 | |
| 161.1518-284.98 | |
| 692 651 M | |
| 1069.0386 | |
| 2 492 M | |
| 28 299 M | |
| 0.0206 | |
| 0.192 |
Our easy-to-use no-coding solutions help you get the data effortlessly:
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
General: {
Code:
'GILD34',
Type:
'Common Stock',
Name:
'Gilead Sciences Inc',
Exchange:
'SA',
CurrencyCode:
'BRL',
CurrencyName:
'Brazilian real',
CurrencySymbol:
'R$',
CountryName:
'Brazil',
CountryISO:
'BR',
OpenFigi:
NULL,
ISIN:
NULL,
CIK:
NULL,
EmployerIdNumber:
NULL,
FiscalYearEnd:
'December',
IPODate:
NULL,
InternationalDomestic:
NULL,
Sector:
'Healthcare',
Industry:
'Drug Manufacturers - General',
}
Gilead Sciences Inc Fundamental Data is available in our Financial Data APIs
- Net Revenue 28 299 M
- EBITDA 14 053 M
- Earnings Per Share 0.26
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get Gilead Sciences Inc Earnings via APIs
- Latest Release NaN
- EPS/Forecast NaN
Get Gilead Sciences Inc End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Get Gilead Sciences Inc latest news via APIs
Gilead Sciences Rides Covid Treatment To Another Beat And Raise
Gilead Sciences rode its Covid treatment to a third-quarter beat and raise late Wednesday, and Gilead stock popped. Continue reading View comments
Do you have any questions?
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
